bump pt reiter
rais estim pt
updat model rais project
project compound-annual-growth-rate revenue ep
increas estim increas revenu ep
primari driver lower tax rate
estim revis new vs old vs consensu estim
ibranc ex-u neg price adjust caus concern still
expect ibranc achiev global sale investor found
neg true ex-u ibranc concern unclear
ex-u ibranc sale conserv decreas ex-u
ibranc sale estim still project signific sale
ex-u us global long-term
project assumpt early-stag breast cancer trial succeed
pt repres potenti upsid jan close plu
offer dividend yield increas pt old ep
new ep price-to-earnings multipl discount
peer median reflect averag near-term growth compound-annual-growth-rate
revenu ep off-set acceler growth compound-annual-growth-rate
revenu ep patent expir fade growth
driver ibranc acceler assum earli stage breast cancer trial succeed
intent leverag compani strong global infrastructur cash flow
enhanc financi prospect also note sinc
perman access ex-u cash compani could take us debt
would abl tax reform
possibl stock driver potenti ibranc sale perform
drug newsflow bavencio phase lung cancer
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
javelin lung trial readout earli bavencio phase platinum
resist ovarian cancer javelin ovarian trial complet march
 xeljanz fda action ulcer coliti june exhibit
act financi advisor inc connect
review strateg altern consum healthcar busi
announc octob guarante transact
ultim pursu consumm pleas review note end
base case ep compar major pharma peer
group average believ averag near-term growth
compound-annual-growth-rate revenu ep off-set acceler growth
compound-annual-growth-rate revenu ep patent
expir fade growth driver ibranc acceler
ep
ep
oncolog franchis financi upsid drive ep forecast strateg
action enhanc growth prospect cancer drug financi leverag drive
combin ep upsid stock multipl expand conjunct
strateg activ enhanc growth prospect
ep
ep
deliv strong financi perform includ ibranc forecast
ibranc global sale ramp strongli drive upward pressur consensu
expect benefit tax reform option help support
ep
ep
financi strateg action disappoint revenu fall short due
competit pressur ep miss price-to-earnings contract due financi
disappoint plu investor concern either lack strateg action
high price paid deal
overweight pfizer share given
revenu growth acceler
patent expir pressur fade
potenti greater
sharehold return bull case event
financi strateg upsid
financi result rel expect
custom develop commerci
govern payer
risk achiev price
upsid risk core busi upsid
extern transact boost
downsid risk revenu shortfal
caus ep miss price-to-earnings contract due
pipelin disappoint overpay
neg drug price develop
estim pipelin contribut total revenu
larg number pipelin candid develop project pipelin
sale follow
top three parp inhibitor talazoparib
anti-ngf tanezumab pan-her inhibitor dacomitinib pleas
contact offic version model
adcom ulcer coliti
pdufa ulcer coliti
ph may pivot duchenn muscular dystrophi
ph may pivot elect spinal surgeri strive
new vs old vs consensu estim
consensu model pipelin contribut includ ibranc adjuv ramp
price
price
price
compani data thomson reuter morgan stanley research valuat methodolog risk associ price target referenc
research report pleas contact client support follow us/canada hong kong latin america
 london singapor sydney tokyo altern may
contact invest repres morgan stanley research broadway attent research manag new york ny usa
us major pharma includ
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
